This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Alabama
Licensed Alabama practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Alabama buyers need their own professional license and NPI; the wholesale drug distributor permit is the supplier’s obligation, not the purchaser’s.
Alabama has considered stem cell legislation more than once without enacting any, so federal law is the only layer that reaches regenerative products here. What Alabama does regulate closely is who performs delegated aesthetic procedures: the Board of Medical Examiners treats the use of lasers and other energy devices as the practice of medicine, with registration and training requirements attached.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Alabama? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Alabama
ExaVeyra ships to licensed practices in all 50 states, Alabama included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Alabama professional license in good standing, verifiable through the licensee search of the Alabama Board of Medical Examiners or the Alabama Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- An Alabama sales and use tax certificate of exemption from the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Alabama permits wholesale drug distributors through the State Board of Pharmacy, and the trigger is shipping: section 34-23-32 reaches anyone who ships, or causes to be shipped, a legend drug or device into Alabama without a valid Board permit, so the regime covers prescription drugs and devices and reaches brokers that never warehouse product. The Board’s facility categories include a Virtual Wholesaler designation for exactly that model. The permit sits with the distributor shipping into the state, not with the purchasing practice.
Ala. Code §§ 34-23-1, 34-23-32; Ala. Admin. Code ch. 680-X-2 · Alabama State Board of Pharmacy
Alabama regenerative-medicine law
Alabama has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Alabama statute addresses unapproved regenerative therapy, so federal law is the only layer that governs it here. The nearest enactment is the Gabe Griffin Right to Try Act (SB 357, 2015), which lets a terminally ill patient access an investigational drug, biological product, or device that has completed Phase 1 trials; it is an access law for terminal illness, not a stem cell authorization. The legislature has looked at going further and declined: SB 16 of 2018, the Steve Bowman Act, would have extended right-to-try access to investigational stem cell treatments and died in committee, and SB 299 of 2025 would have authorized stem cell therapy on the Florida pattern and was not enacted. Practice in this area is governed by the Medical Practice Act, the Nurse Practice Act, and the boards that administer them, alongside federal law.
How this applies to exosomes
Alabama has no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee; bills that would have created one, SB 16 in 2018 and SB 299 in 2025, were introduced and not enacted. There is therefore no Alabama definition to read exosomes into or out of, and even the proposed bills were written around stem cells and tissue-based products rather than acellular extracellular vesicles. Exosome products in Alabama are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Alabama practice
Alabama is a two-board approval state for advanced practice: CRNP collaborative practice applications are approved jointly by the Board of Medical Examiners and the Board of Nursing, so paperwork runs through both agencies before practice begins. For device-based aesthetic work, chapter 540-X-11 adds a separate layer: physician registration with the Board, written protocols for each delegated non-ablative treatment, mandated initial training hours, and delegating-physician supervision with personal evaluation of complications.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Alabama Board of Medical Examiners may perform medical acts within their scope and are the source of any delegation. A physician who proposes to perform laser, light-based, or other energy-based device procedures registers with the Board first under chapter 540-X-11, and delegates non-ablative treatments only through written protocols to trained delegates, with training hours mandated for both the physician and the delegate. |
| NP / APRN | Certified registered nurse practitioners practice under a collaborative practice agreement with a physician, approved jointly by the Board of Medical Examiners and the Board of Nursing. The agreement specifies approved duties, skills, and prescribing privileges and sets out quality assurance plans, and the collaborating physician carries continuing education obligations tied to the collaboration. |
| PA | Physician assistants are licensed through the Board of Medical Examiners and practice under physician supervision within a board-approved scope. |
| RN | Registered nurses may perform delegated treatments within their license and the physician-approved protocol, and only after a prescriber has examined the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
An examination by a prescriber precedes delegated treatment in Alabama, and for energy-device procedures chapter 540-X-11 places supervision and the care of complications personally on the delegating physician. Confirm current expectations with the Alabama Board of Medical Examiners, whose rules govern this area in detail.
Ownership and clinic licensing
Alabama regulates medical practice through the Board of Medical Examiners and the Medical Licensure Commission, and physician-owned professional entities with management services arrangements are the usual structures. No bright-line corporate practice statute of the Texas or New York kind was found in primary sources, and the practical constraints in Alabama come from the delegation and device rules rather than from an ownership percentage, so treat entity structure as a question for Alabama counsel before opening.
Cold chain into Alabama
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Alabama order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Birmingham | Jefferson | Largest Alabama market, anchored by a major academic medical center. |
| Huntsville | Madison | Fast-growing north Alabama market with a strong professional base. |
| Montgomery | Montgomery | Capital market serving central Alabama. |
| Mobile | Mobile | Gulf Coast market with dermatology and aesthetic coverage. |
| Tuscaloosa | Tuscaloosa | University market west of Birmingham. |
| Auburn | Lee | East Alabama market serving the Georgia border. |
- Alabama orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot’s Certificate of Analysis; store to the labeled conditions on arrival.
Wholesale exosome supply by city in Alabama
Each city page covers local receiving conditions, delivery disruptions and business license rules for Alabama practices in that area.
Practice types we supply in Alabama
Alabama licensing and verification
Alabama Board of Medical Examiners and Medical Licensure Commission
Licenses physicians, PAs, and CRNPs; CRNP collaborative practice is approved here jointly with the Board of Nursing.
Alabama Board of Nursing
Alabama State Board of Pharmacy
Issues the wholesale drug distributor permits held by suppliers shipping into Alabama.
Alabama Department of Revenue
Sales and use tax registration and certificates of exemption.
Alabama sourcing questions
- Does Alabama have a stem cell law?
- No. Alabama has considered one more than once without enacting any: SB 16 of 2018, the Steve Bowman Act, would have extended right-to-try access to investigational stem cell treatments and died in committee, and SB 299 of 2025 would have authorized stem cell therapy on the Florida pattern and was not enacted. With no state statute, exosome products in Alabama are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- What does Alabama’s Right to Try Act cover?
- The Gabe Griffin Right to Try Act (SB 357, 2015) lets a terminally ill patient, with physician recommendation and informed consent, access an investigational drug, biological product, or device that has completed Phase 1 clinical trials. It is an access law for terminal illness, not a stem cell or regenerative medicine authorization, and it says nothing about aesthetic practice.
- What are Alabama’s rules for lasers and energy devices in med spas?
- The Board of Medical Examiners treats the use of lasers, pulsed light, and any other energy source or modality affecting living tissue as the practice of medicine under Ala. Admin. Code chapter 540-X-11. A physician registers with the Board before performing such procedures, may delegate non-ablative treatments only through written protocols to trained delegates, and remains responsible for supervision and for personally evaluating complications. Training hours are mandated for both the physician and the delegate.
- What does an Alabama nurse practitioner need in place?
- A collaborative practice agreement with a physician, approved jointly by the Board of Medical Examiners and the Board of Nursing. The agreement specifies approved duties, skills, and prescribing privileges and sets out quality assurance plans. Alabama is a restrictive state for advanced practice, so the paperwork precedes the practice and runs through two boards.
- Does my Alabama clinic need a wholesale distributor permit to buy exosomes?
- No. The wholesale drug distributor permit under Ala. Code 34-23-32 is held by the supplier that ships, or causes to be shipped, product into Alabama, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA said so directly in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Alabama?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Alabama Legislature (ALISON), bills and the Code of Alabama (accessed 16 October 2026)
- Alabama SB 357 (2015), Gabe Griffin Right to Try Act, bill text (accessed 16 October 2026)
- Ala. Admin. Code ch. 680-X-2, Alabama State Board of Pharmacy rules (accessed 16 October 2026)
- Alabama State Board of Pharmacy, facility permit categories (accessed 16 October 2026)
- Alabama Board of Medical Examiners and Medical Licensure Commission (accessed 16 October 2026)
- Alabama Board of Nursing (accessed 16 October 2026)
- Alabama Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page describes.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard that MISEV2023 updates; together they define what a complete exosome characterization package contains.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical use runs through regulated research.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.